Replimune Group, Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was USD 174.28 million compared to USD 118.04 million a year ago. Basic loss per share from continuing operations was USD 2.99 compared to USD 2.26 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.67 USD | -0.46% | +10.67% | +3.32% |
24/06 | Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index | CI |
13/06 | Replimune Group Signs $100 Million PIPE Deal with Institutional Investors | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.32% | 535M | |
+22.03% | 46.93B | |
+37.63% | 39.08B | |
-8.31% | 38.48B | |
+30.99% | 31.01B | |
-13.75% | 26.14B | |
+11.12% | 25.88B | |
+35.06% | 12.53B | |
-6.55% | 11.36B | |
-12.64% | 10.65B |
- Stock Market
- Equities
- REPL Stock
- News Replimune Group, Inc.
- Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023